Zobrazeno 1 - 10
of 117
pro vyhledávání: '"Class III antiarrhythmic agent"'
Publikováno v:
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
© 2021 The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
We have experimented with isolated cardiomyocytes of mollusks Helix. During the whole-cell patch-clamp recordings of K+ currents a c
We have experimented with isolated cardiomyocytes of mollusks Helix. During the whole-cell patch-clamp recordings of K+ currents a c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30d5ada3ad1ada23507e46e044033a7c
https://doi.org/10.1007/s00232-021-00195-w
https://doi.org/10.1007/s00232-021-00195-w
Autor:
V. G. Valiev, A. E. Radzevich, V. A. Gorshkov, E. M. Zeltyn, A. B. Besprozvanny, E. N. Ostroumov
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 4, Iss 6, ч.II, Pp 70-76 (2005)
Aim. To study clinical efficacy of a new, class III, antiarrhythmic agent, nibentan, in various supraventricular (SV) cardiac arrythmias. Material and methods. In total, 153 patients with atrial fibrillation, atrial flutter, or SV tachycardia were ex
Externí odkaz:
https://doaj.org/article/8d4907d427234348b5cae923e20366e6
Publikováno v:
Asian Journal of Ophthalmology. 17:170-172
Vortex keratopathy is a common side effect of amiodarone, which is a class III antiarrhythmic agent. We describe a 50-year-old man who developed vortex keratopahy with amiodarone 200 mg BD for atrial fibrillation since two years. The daily (400 mg/da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24dba0f38989f97d976c848c02ffedd7
https://doi.org/10.35119/asjoo.v17i2.553
https://doi.org/10.35119/asjoo.v17i2.553
Autor:
Naoya Fukushima, Takuya Tamame, Mika Saito, Kazuhiko Shibuya, Shino Jimbo, Masaru Miura, Hirotaka Ohki, Kazuaki Takabatake, Seiichirou Yokoyama
Publikováno v:
Pediatric Cardiology and Cardiac Surgery. 29:300-305
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93616f14e45e3d1a17ebcf363e7ff2d4
https://doi.org/10.9794/jspccs.29.300
https://doi.org/10.9794/jspccs.29.300
Publikováno v:
Drug Development Research. 71:303-312
CPUY11018 has anti-atrial fibrillation (AF) effects in rats. The effects of CPUY11018 on the transient outward K+ current (Ito) and ultra-rapid delayed rectifier K+ current (IKur) were studied using whole-cell patch clamp techniques and an acetylchol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b37984022ec55c37d60597bcc4513da0
https://doi.org/10.1002/ddr.20375
https://doi.org/10.1002/ddr.20375
Autor:
V. P. Lezina, N. I. Avdyunina, V. I. Prokof’eva, L. N. Grushevskaya, B. M. Pyatin, O. B. Stepanenko
Publikováno v:
Pharmaceutical Chemistry Journal. 41:440-443
Cardiocyclide, a new Russian class III antiarrhythmic agent, was developed at the State V. V. Zakusov Science Research Institute Pharmacology, Russian Academy of Medical Sciences. The aims of the present work were to study the physicochemical propert
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff8e6c2d615a16622443627a5f588e40
https://doi.org/10.1007/s11094-007-0096-0
https://doi.org/10.1007/s11094-007-0096-0
Autor:
Kaichiro Kamiya, Mari Amino, Harumichi Nakagawa, Itsuo Kodama, Masatoshi Yamazaki, Ichiro Sakuma, Yuko S. Ishiguro, Yusuke Okuno, Haruo Honjo
Publikováno v:
American Journal of Physiology-Heart and Circulatory Physiology. 292:H539-H548
Nifekalant (NF) is a novel class III antiarrhythmic agent that is effective in preventing life-threatening ventricular tachycardia/fibrillation (VT/VF). We investigated mechanisms of destabilization and early termination of spiral-type reentrant VT b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b30e5a9940187d47264b414fd25465f
https://doi.org/10.1152/ajpheart.00640.2006
https://doi.org/10.1152/ajpheart.00640.2006
Autor:
Laura Brantman, Jill N. Howie
Publikováno v:
Critical Care Nurse. 26:48-58
Laura Brantman is an acute care nurse practitioner at the University of California, San Francisco. Jill Howie is an associate clinical professor at the University of California, San Francisco and a nurse practitioner at Kaiser Permanente. including d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcfad9aac11afd5edced8de1ace94ca7
https://doi.org/10.4037/ccn2006.26.1.48
https://doi.org/10.4037/ccn2006.26.1.48
Publikováno v:
Journal of Investigative Medicine. 49:346-352
Background Although amiodarone has been referred to as a class III antiarrhythmic agent, it also possesses electrophysiologic characteristics of the three other classes (classes I and IV and minor class II effects). Previous studies have demonstrated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dd3c70fe3fec6667290bcebb5790086
https://doi.org/10.2310/6650.2001.33900
https://doi.org/10.2310/6650.2001.33900
Publikováno v:
Heart Drug. 1:320-331
Atrial fibrillation and atrial flutter, the most common forms of supraventricular tachyarrhythmias, are associated with a high risk of embolic complications, tachycardia-induced ventricular dysfunction, and disabling symptoms. Pharmacological therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::715f6dcbbb795e94d926c8aaa56d4a75
https://doi.org/10.1159/000048982
https://doi.org/10.1159/000048982